573763-07-2

Usage

Uses

Used in Organic Synthesis:
2-Pyridinecarbonitrile,5-amino-3-fluoro-(9CI) is used as a building block in organic synthesis for the preparation of various pharmaceuticals, agrochemicals, and organic compounds. Its versatile functional groups allow for further chemical modifications and reactions, making it a valuable intermediate in the synthesis of complex organic molecules.
Used in Medicinal Chemistry and Drug Discovery:
2-Pyridinecarbonitrile,5-amino-3-fluoro-(9CI) is used as a starting material in the development of new pharmaceuticals. Its unique structure and functional groups can be exploited to design and synthesize novel drug candidates with potential therapeutic applications. 2-Pyridinecarbonitrile,5-amino-3-fluoro-(9CI) may also possess biological and pharmacological activities, making it a subject of interest for research in the field of medicinal chemistry.
Used in Agrochemicals:
2-Pyridinecarbonitrile,5-amino-3-fluoro-(9CI) is used as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its structural features can be tailored to develop new agrochemicals with improved efficacy, selectivity, and environmental compatibility.

InChI:InChI=1/C6H4FN3/c7-5-1-4(9)3-10-6(5)2-8/h1,3H,9H2

Upstream product

• 1344734-69-5 C₆H₃FN₂O 
• 1344734-70-8 C₆H₂FN₃O₃ 
• 97509-75-6 3-fluoropicolinonitrile 
• 573763-02-7 3-fluoro-5-nitropicolinonitrile 
• 7439-89-6 iron 

Downstream Products

• 1344734-71-9 C₂₃H₂₅F₂N₅O₃ 
• 1344734-75-3 C₃₂H₃₃F₂N₇O₅S 
• 1419598-41-6 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(5-fluoro-6-(hydroxymethyl)pyridin-3-yl)urea 

Relevant academic research and scientific papers

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1 is H or C1-6 alkyl, R2 is H or C1-6 alkyl or CH20H, R3 is H or C1-6 alkyl, and R4 is H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, then R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl or-CH20H, and when R2, R3, and R4 are H, then R1 is C 1-6 alkyl; A is 1 ) a 9-10 membered bicyclic heterocycle having 1-3 heteroatoms independently selected from N, S and 0, which 9-10 membered bicyclic heterocycle is unsubstituted or substituted with R5 and unsubstituted or substituted with R6 and unsubstituted or substituted with NH2, or 2) a 6-9 membered monocyclic or bicyclic carbocyclic ring system unsubstituted or substituted with R5, unsubstituted or substituted with R6, and unsubstituted or substituted with -CH2NH2; and B is 1) a 5- or 6-membered monocyclic heterocycle having 1 or 2 heteroatoms independently selected from N, S or 0, which is unsubstituted or substituted on a carbon or nitrogen atom with R7, unsubstituted or substituted on a carbon or nitrogen atom with R8, and unsubstituted or substituted on a carbon or nitrogen atom with R9, or 2) an 8- or 9-membered fused bicyclic heterocycle having 1, 2 or 3 nitrogen atoms which is unsubstituted or substituted on a carbon or nitrogen atom with R7, and unsubstituted or substituted on a carbon or nitrogen atom with R8; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses.

SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats

A novel series of pyridyl carboxamide-based CCR5 inhibitors was designed, synthesized, and demonstrated to be highly potent against HIV-1 infection in both HOS and PBL assays. Attempts to evaluate this series of compounds in a rat PK model revealed its instability in rat plasma. A hypothesis for this liability was proposed, and strategies to overcome this issue were pursued, leading to discovery of highly potent 40 and 41, which featured dramatically improved rat PK profiles. 2011 Elsevier Ltd. All rights reserved.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.